Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Прекращено Фаза III Россия

Tecemotide (L-BLP25) and Hormonal Treatment; Placebo of tecemotide (L-BLP25) and Hormonal Treatment; cyclophosphamide; sodium chloride (NaCl)

A Randomized, Double-blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Post-menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer

Номер протоколаEMR 200038-010
ФазаФаза III
Участников по плану — во всех странах исследования16
Сроки01.09.2009 — 01.08.2010
Начало: 1 сентября 2009Окончание: 1 августа 2010
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00925548/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование прекращено досрочно, новых участников не набирают.
  • Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 16 чел. во всех странах исследования.
  • Плановая дата окончания (08.2010) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолТолько женщины
Здоровые добровольцынет

Главное из критериев

  • Состояние пациента (ECOG)0–1
  • Биомаркеры в критерияхГормональные рецепторы (ER/PR)
  • Опухольнужен измеримый очаг (RECIST)
  • Стадияметастатическая (IV), местно-распространённая (III)
  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 26

Критерии включения

  • Postmenopausal women as defined in the protocol
  • Estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, histologically or cytologically confirmed primary carcinoma of the breast
  • Expressing at least one of the following five human leukocyte antigen (HLA) haplotypes, as centrally assessed by HLA genotyping from whole blood: HLA-A2, -A3, -A11, -B7, or -B35
  • Locally advanced, recurrent, or metastatic breast cancer (Subject must have at least one lesion not located in bone)
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), and inoperable
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematologic, hepatic, and renal function within two weeks prior to initiation of therapy, as defined by the protocol
  • Other protocol-defined inclusion criteria may apply

Критерии невключения

  • Disease Status
  • PD either during hormonal therapy for early breast cancer (adjuvant therapy) or within 48 months from the initiation of such therapy
  • Human epidermal growth factor receptor 2-positive (HER2+) breast cancer as defined in the protocol
  • Autoimmune disease that in the opinion of the investigator could compromise the safety of the subject in this study (Exception will be granted for well-controlled Type I diabetes mellitus)
  • Recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; hereditary or congenital immunodeficiencies
  • Past or current history of malignant neoplasm other than breast cancer (BRCA), except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least five years
  • Known active Hepatitis B infection or carrier state and/or Hepatitis C infection, known Human Immunodeficiency Virus infection, or any other infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response or could expose her to the likelihood of more and/or severe side effects
  • Pre-therapies
  • Receipt of immunotherapy (for example \[e.g.\], interferons; tumor necrosis factor; interleukins; growth factors granulocyte macrophage-colony stimulating factor \[GM-CSF\], granulocyte-colony stimulating factor \[G-CSF\], macrophage-colony stimulating factor \[M-CSF\], or monoclonal antibodies), or chemotherapy, within four weeks (28 days) prior to randomization. Note: Subjects who have received monoclonal antibodies for imaging are eligible
  • Prior receipt of investigational systemic drugs (including off-label use of approved products) or any kind of systemic treatment (chemotherapy, or immunotherapy), with the exception of hormonal therapy (HT) when given for a period not exceeding 4 weeks (28 days) prior to randomization, for treatment of inoperable, locally advanced, recurrent, or metastatic breast cancer
  • Prior radiotherapy to the site of cancer, if only one site will be used for evaluation of tumor response
  • Prior use of bisphosphonates or concurrent use while on study treatment is allowed
  • Physiological Function
  • Central nervous system disease or brain metastases, as documented by computed tomography (CT) or magnetic resonance imaging (MRI)
  • Medical or psychiatric conditions that would interfere with the ability to provide informed consent, communicate side effects, or comply with protocol requirements
  • Clinically significant cardiac disease, e.g., cardiac failure of New York Heart Association (NYHA) classes III-IV; uncontrolled angina pectoris, uncontrolled arrhythmia, uncontrolled hypertension, or myocardial infarction in the previous six months, as confirmed by an electrocardiogram (ECG)
  • Splenectomy
  • Standard Criteria
  • Need for concurrent treatment with a non-permitted therapy (e.g., concurrent chemotherapy, radiotherapy, systemic immunosuppressive drugs, use of herbal medicines or botanical formulations intended to treat cancer) while on protocol therapy. Palliative radiation to painful bone lesions is allowed
  • Participation in another clinical study within 30 days prior to randomization
  • Known hypersensitivity to the study drugs
  • Known alcohol or drug abuse
  • Legal incapacity or limited legal capacity
  • Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
  • Subject who could be regarded as "vulnerable" according to International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines (e.g., the subject's willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate, plus persons kept in detention; persons in nursing homes; subjects in emergency situations; homeless persons; and nomads)
  • Any other reason that, in the opinion of the investigator, precludes the subject from participating in this study

Источник: ClinicalTrials.gov, NCT00925548 · запись обновлена в реестре 24 июля 2014.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)16
Почему остановлено (как в реестре): See termination reason in the below Purpose statement
Что измеряют — первичные конечные точки (1), вторичных — 10
  • Progression-Free Survival (PFS) — Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized i.e. 30 Sep 2009, until end of trial i.e. 27 Aug 2010

Цель исследования

EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00925548 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.